BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kalambokis GN, Mouzaki A, Rodi M, Tsianos EV. Rifaximin improves thrombocytopenia in patients with alcoholic cirrhosis in association with reduction of endotoxaemia. Liver Int. 2012;32:467-475. [PMID: 22098272 DOI: 10.1111/j.1478-3231.2011.02650.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Tenorio AR, Chan ES, Bosch RJ, Macatangay BJ, Read SW, Yesmin S, Taiwo B, Margolis DM, Jacobson JM, Landay AL. Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286. J Infect Dis. 2015;211:780-790. [PMID: 25214516 DOI: 10.1093/infdis/jiu515] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 6.9] [Reference Citation Analysis]
2 Mitchell O, Feldman DM, Diakow M, Sigal SH. The pathophysiology of thrombocytopenia in chronic liver disease. Hepat Med. 2016;8:39-50. [PMID: 27186144 DOI: 10.2147/hmer.s74612] [Cited by in Crossref: 18] [Cited by in F6Publishing: 47] [Article Influence: 3.6] [Reference Citation Analysis]
3 Kuracha MR, Thomas P, Tobi M, McVicker BL. Role of cell-free network communication in alcohol-associated disorders and liver metastasis. World J Gastroenterol 2021; 27(41): 7080-7099 [DOI: 10.3748/wjge.v27.i41.7080] [Reference Citation Analysis]
4 Zeng X, Tang XJ, Sheng X, Ni W, Xin HG, Chen WZ, Jiang CF, Lin Y, Shi J, Shi B, Chen YX, Yuan ZL, Xie WF. Does low-dose rifaximin ameliorate endotoxemia in patients with liver cirrhosis: a prospective study. J Dig Dis 2015;16:665-74. [PMID: 26474237 DOI: 10.1111/1751-2980.12294] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
5 Bellot P, Francés R, Such J. Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. Liver Int 2013;33:31-9. [DOI: 10.1111/liv.12021] [Cited by in Crossref: 133] [Cited by in F6Publishing: 138] [Article Influence: 14.8] [Reference Citation Analysis]
6 Nishikawa H, Enomoto H, Nishiguchi S, Iijima H. Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis. Int J Mol Sci. 2020;21:5254. [PMID: 32722100 DOI: 10.3390/ijms21155254] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
7 Gnauck A, Lentle RG, Kruger MC. Chasing a ghost?--Issues with the determination of circulating levels of endotoxin in human blood. Crit Rev Clin Lab Sci 2016;53:197-215. [PMID: 26732012 DOI: 10.3109/10408363.2015.1123215] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 7.4] [Reference Citation Analysis]
8 Singal AK, Kamath PS, Gores GJ, Shah VH. Alcoholic hepatitis: current challenges and future directions. Clin Gastroenterol Hepatol 2014;12:555-64; quiz e31-2. [PMID: 23811249 DOI: 10.1016/j.cgh.2013.06.013] [Cited by in Crossref: 89] [Cited by in F6Publishing: 86] [Article Influence: 11.1] [Reference Citation Analysis]
9 Singal AK, Kamath PS, Gores GJ, Shah VH. Alcoholic hepatitis: current challenges and future directions. Clin Gastroenterol Hepatol. 2014;12:555-64; quiz e31-2. [PMID: 23811249 DOI: s1542-3565(13)00872-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Siddiqui MT, Cresci GAM. Microbiota reprogramming for treatment of alcohol-related liver disease. Transl Res 2020;226:26-38. [PMID: 32687975 DOI: 10.1016/j.trsl.2020.07.004] [Reference Citation Analysis]
11 Abdel-Razik A, Mousa N, Shabana W, Refaey M, Elzehery R, Elhelaly R, Zalata K, Abdelsalam M, Eldeeb AA, Awad M, Elgamal A, Attia A, El-Wakeel N, Eldars W. Rifaximin in nonalcoholic fatty liver disease: hit multiple targets with a single shot. Eur J Gastroenterol Hepatol. 2018;30:1237-1246. [PMID: 30096092 DOI: 10.1097/meg.0000000000001232] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
12 Poole LG, Dolin CE, Arteel GE. Organ-Organ Crosstalk and Alcoholic Liver Disease. Biomolecules 2017;7:E62. [PMID: 28812994 DOI: 10.3390/biom7030062] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
13 Zeng T, Zhang CL, Xiao M, Yang R, Xie KQ. Critical Roles of Kupffer Cells in the Pathogenesis of Alcoholic Liver Disease: From Basic Science to Clinical Trials. Front Immunol 2016;7:538. [PMID: 27965666 DOI: 10.3389/fimmu.2016.00538] [Cited by in Crossref: 45] [Cited by in F6Publishing: 50] [Article Influence: 9.0] [Reference Citation Analysis]
14 Jørgensen SF, Macpherson ME, Bjørnetrø T, Holm K, Kummen M, Rashidi A, Michelsen AE, Lekva T, Halvorsen B, Trøseid M, Mollnes TE, Berge RK, Yndestad A, Ueland T, Karlsen TH, Aukrust P, Hov JR, Fevang B. Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency. Sci Rep 2019;9:167. [PMID: 30655568 DOI: 10.1038/s41598-018-35367-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
15 Dunn W, Shah VH. Pathogenesis of Alcoholic Liver Disease. Clin Liver Dis. 2016;20:445-456. [PMID: 27373608 DOI: 10.1016/j.cld.2016.02.004] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 11.8] [Reference Citation Analysis]
16 Vassallo G, Mirijello A, Ferrulli A, Antonelli M, Landolfi R, Gasbarrini A, Addolorato G. Review article: Alcohol and gut microbiota - the possible role of gut microbiota modulation in the treatment of alcoholic liver disease. Aliment Pharmacol Ther. 2015;41:917-927. [PMID: 25809237 DOI: 10.1111/apt.13164] [Cited by in Crossref: 61] [Cited by in F6Publishing: 60] [Article Influence: 10.2] [Reference Citation Analysis]
17 Tsochatzis EA, Bosch J, Burroughs AK. Future treatments of cirrhosis. Expert Rev Gastroenterol Hepatol 2014;8:571-81. [PMID: 24909884 DOI: 10.1586/17474124.2014.902303] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
18 Luo M, Li L, Yang EN, Dai CY, Liang SR, Cao WK. Correlation between interleukin-6 and ammonia in patients with overt hepatic encephalopathy due to cirrhosis. Clin Res Hepatol Gastroenterol. 2013;37:384-390. [PMID: 23084463 DOI: 10.1016/j.clinre.2012.08.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
19 Sung H, Kim SW, Hong M, Suk KT. Microbiota-based treatments in alcoholic liver disease. World J Gastroenterol 2016; 22(29): 6673-6682 [PMID: 27547010 DOI: 10.3748/wjg.v22.i29.6673] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
20 Khungar V, Poordad F. Management of overt hepatic encephalopathy. Clin Liver Dis. 2012;16:73-89. [PMID: 22321466 DOI: 10.1016/j.cld.2012.03.009] [Cited by in Crossref: 44] [Cited by in F6Publishing: 31] [Article Influence: 4.9] [Reference Citation Analysis]
21 Zhou Z, Zhong W. Targeting the gut barrier for the treatment of alcoholic liver disease. Liver Res 2017;1:197-207. [PMID: 30034913 DOI: 10.1016/j.livres.2017.12.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 7.8] [Reference Citation Analysis]
22 Ponziani FR, Gerardi V, Pecere S, D’Aversa F, Lopetuso L, Zocco MA, Pompili M, Gasbarrini A. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. World J Gastroenterol 2015; 21(43): 12322-12333 [PMID: 26604640 DOI: 10.3748/wjg.v21.i43.12322] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
23 Luo M, Guo JY, Cao WK. Inflammation: A novel target of current therapies for hepatic encephalopathy in liver cirrhosis. World J Gastroenterol 2015; 21(41): 11815-11824 [PMID: 26557005 DOI: 10.3748/wjg.v21.i41.11815] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.7] [Reference Citation Analysis]
24 Luo M, Li L, Yang EN, Cao WK. Relationship between interleukin-6 and ammonia in patients with minimal hepatic encephalopathy due to liver cirrhosis. Hepatol Res. 2012;42:1202-1210. [PMID: 22646055 DOI: 10.1111/j.1872-034x.2012.01047.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
25 Spengler EK, Dunkelberg J, Schey R. Alcoholic hepatitis: current management. Dig Dis Sci. 2014;59:2357-2366. [PMID: 24798996 DOI: 10.1007/s10620-014-3173-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
26 Caraceni P, Vargas V, Solà E, Alessandria C, de Wit K, Trebicka J, Angeli P, Mookerjee RP, Durand F, Pose E, Krag A, Bajaj JS, Beuers U, Ginès P; Liverhope Consortium. The Use of Rifaximin in Patients With Cirrhosis. Hepatology 2021. [PMID: 33421158 DOI: 10.1002/hep.31708] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
27 Kuracha MR, Thomas P, Tobi M, McVicker BL. Role of cell-free network communication in alcohol-associated disorders and liver metastasis. World J Gastroenterol 2021; 27(41): 7080-7099 [DOI: 10.3748/wjg.v27.i41.7080] [Reference Citation Analysis]
28 Mullen KD, Sanyal AJ, Bass NM, Poordad FF, Sheikh MY, Frederick RT, Bortey E, Forbes WP. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol 2014; 12: 1390-7. e2. [PMID: 24365449 DOI: 10.1016/j.cgh.2013.12.021] [Cited by in Crossref: 116] [Cited by in F6Publishing: 94] [Article Influence: 14.5] [Reference Citation Analysis]
29 Finlin BS, Zhu B, Boyechko T, Westgate PM, Chia CW, Egan JM, Kern PA. Effect of Rifaximin Treatment on Endotoxemia and Insulin Sensitivity in Humans. J Endocr Soc. 2019;3:1641-1651. [PMID: 31428718 DOI: 10.1210/js.2019-00148] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
30 Gangarapu V, Ince AT, Baysal B, Kayar Y, Kılıç U, Gök Ö, Uysal Ö, Şenturk H. Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2015;27:840-5. [PMID: 26043290 DOI: 10.1097/MEG.0000000000000348] [Cited by in Crossref: 72] [Cited by in F6Publishing: 40] [Article Influence: 14.4] [Reference Citation Analysis]
31 Fukui H. Gut Microbiome-based Therapeutics in Liver Cirrhosis: Basic Consideration for the Next Step. J Clin Transl Hepatol 2017;5:249-60. [PMID: 28936406 DOI: 10.14218/JCTH.2017.00008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
32 Fukui H. Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia. World J Hepatol 2015; 7(3): 425-442 [PMID: 25848468 DOI: 10.4254/wjh.v7.i3.425] [Cited by in Crossref: 99] [Cited by in F6Publishing: 87] [Article Influence: 16.5] [Reference Citation Analysis]